12.00
+0.78(+6.95%)
Currency In USD
| Previous Close | 11.22 |
| Open | 11.36 |
| Day High | 12.33 |
| Day Low | 11.4 |
| 52-Week High | 18.2 |
| 52-Week Low | 9.24 |
| Volume | 3.96M |
| Average Volume | 1.57M |
| Market Cap | 3.75B |
| PE | 0 |
| EPS | 0 |
| Moving Average 50 Days | 10.29 |
| Moving Average 200 Days | 10.64 |
| Change | 0.78 |
Data not available
Fennec Pharmaceuticals to Participate in Upcoming Investor Conference
GlobeNewswire Inc.
Nov 13, 2024 11:27 AM GMT
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the 15th Annual Crai
Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire Inc.
Nov 07, 2024 11:13 AM GMT
~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic Investments to Drive Awareness of Ototoxicity & Adoption of PEDMA
Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
GlobeNewswire Inc.
Oct 31, 2024 10:23 AM GMT
RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2024 financia